Treprostinil Sodium Inhalation for Patients At High Risk for ARDS
Status:
Terminated
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a
number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung
function and breathlessness. There are no pharmacological treatments approved for the
treatment of ARDS. This pilot trial will study the safety and efficacy of Treprostinil sodium
by inhalation for preventing the progression of acute hypoxemic respiratory failure to
positive pressure ventilation and/or ARDS in patients at high risk.